Immunology Collaboration and Licensing Agreements Trends Report 2024: Explore 862 Detailed Contract Documents via SEC Submissions - Access Deal Payment Terms and Trigger Clauses
October 14, 2024 06:46 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Autoimmune Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 905 Deals Signed Since 2016 - Upfront, Milestone, Royalties Data by Company A-Z, Therapy Focus and Technology
September 25, 2024 09:10 ET
|
Research and Markets
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report 2024-2030, with Coverage of Akeso, Alphamab Oncology, BioAtla, BioNTech, Sino Biological and Xencor
September 04, 2024 09:41 ET
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report" has been added to ResearchAndMarkets.com's...
Celiac Disease Drugs Market - Global First Line of Treatment, Second Line of Treatment, Steroids & Immunosuppressive Drugs, Therapeutic Vaccines, Vitamins & Dietary Supplements Forecast 2024-2030
August 28, 2024 06:03 ET
|
Research and Markets
Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "Global Celiac Disease Drugs Market by Drug (First Line of Treatment, Second Line of Treatment), Type (Steroids & Immunosuppressive Drugs,...
AstriVax enters clinical phase with its novel vaccine platform technology
June 24, 2024 01:00 ET
|
AstriVax
The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with AstriVax technology. The study will also provide...
Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type
May 16, 2024 10:45 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Autoimmune Collaboration and Licensing Deals Report 2024: Provides Details of 882 Autoimmune Deals Dating Back to 2016 by Company, Headline Value, Therapeutic Area and Technology Type
April 24, 2024 04:24 ET
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Autoimmune Collaboration and...
Histone Deacetylase 6 Drug Pipeline Research Report 2024: Comprehensive Insights about 20+ Companies and 26+ Pipeline Drugs
April 12, 2024 10:06 ET
|
Research and Markets
Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Histone Deacetylase 6 - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Global Anticancer Drug Market Estimated to Reach USD 172.52 Billion in 2023 with Continued Growth Projected Through 2029
April 03, 2024 11:51 ET
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ...
CAR-T Funding Report 2024: Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions
March 18, 2024 04:52 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024" report has been added to ...